Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer

BMC Cancer

Volumn 5, Issue , 2005, Pages

  Abacioglu, Ufuk ^a   Yumuk, Perran F ^a   Caglar, Hale ^a   Sengoz, Meric ^a   Turhal, Nazim S ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; RADIOSENSITIZING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METASTASIS; NAUSEA AND VOMITING; PATIENT SELECTION; PNEUMONIA; PROGNOSIS; RADIATION DOSE; RADIATION PNEUMONIA; SURVIVAL TIME; TREATMENT PLANNING; BONE MARROW CELL; COMPUTER ASSISTED RADIOTHERAPY; CYTOLOGY; DISEASE COURSE; DISEASE FREE SURVIVAL; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TIME; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW CELLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, CONFORMAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 26944449346     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-5-71     Document Type: Article

References (35)

1. Lung. In American Joint Committee on Cancer. Cancer Staging Handbook 6th edition. Edited by: Greene FL and others. New York: Springer-Verlag; 2002:189-203.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909.
3. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: A meta-analysis. Ann Intern Med 1996, 125:723-729.
4. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy, alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB Nonsmall cell lung cancer: A meta-analysis. Cancer 1995, 76:593-601.
5. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
6. Curran WJ, Scoot C, Langer C, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal S, Byhardt R, Sause W, Cox J: Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer. Initial report of RTOG 9410 [abstract]. Proc Am Soc Clin Oncol 2000, 19:A1891.
7. Schaake-Koning C, Van Den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Van Houtte P, Kirkpatrick A, Koolen M, Maat B. Nijs A: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992, 326:524-530.
8. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
9. Choy H: Combination chemoradiotherapy with gemcitabine: Potential applications. Oncology (Williston Park) 2000, 14(Suppl 4):20-25.
10. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS: Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000, 47:785-791.
11. Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999, 59:107-114.
12. National Cancer Institute: Common Toxicity Criteria. Bethesda, MD; 1988.
13. Miller AB, Hogestraeten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981, 47:207-214.
14. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd, Green MR: A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III NSCLC. N Engl J Med 1990, 323:940-945.
15. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR: Improved survival in stage III NSCLC: Seven year follow up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996, 88:1210-1215.
16. Gonzalez E, Sanchez-Rovira P, Jaen A, Porras I, Medina B, Duenas R, Mohedano N, Fernandez M, Lozano A: Phase I study concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC [abstract]. Eur J Cancer 1999, 35(suppl 4):A1054.
17. Zinner R, Fossella FV, Komaki R, Delclos M, Jung M, Bonnie G, Jin L, Pisters K, Jhingran A, Waun H: Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus cisplatin (CDDP), for patients with stage III and medically inoperable stage II non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1999, 18:A1798.
18. Gregor A, Price A, Van Der Leest AHD, Scalliet P, Wets M, Jungnelius U, Lemmens JP, Groen HJ: Phase I study of gemcitabine and radiotherapy in stage III non-small call lung cancer [abstract]. Proc Am Soc Clin Oncol 1999, 18:A1953.
19. Athanasiou E, Cyrgias G, Boinis K, Samantas E, Christodoulidou M, Tamvaki F, Panoussaki E: Concurrent chemoradiotherapy with Gemcitabine for locally advanced non-small cell lung cancer (NSCLC): Preliminary results of a phase II study [abstract]. Ann Oncol 1998, 9(Suppl 4):A468.
20. Scalliet P, Goor C, Galdermans D, Van Meerbeek J, Groen HJ, Van de Leest AHD, Westerink H, Jungnelius U, Turrisi A: Gemzar (Gemcitabine) with thoracic radiotherapy- A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1998, 17:A1923.
21. Vokes EE, Leopold KA, Herndon JE, Crawford J, Perry MC, Miller AA, Green MR. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC) (CALGB Study 9431) [abstract]. Proc Am Soc Clin Oncol 1999, 18:A1771.
22. Blackstock AW, Lesser GJ, Fletcher-Steede J, Case LD, Tucker RW, Russo SM, White DR, Miller A: Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 51:1281-1289.
23. McMullen KP, Miller AA, Case LD, Lesser G, Culbreth M, Patton S, Tucker R, Blackstock AW: Thoracic radiation and concurrent gemcitabine: A phase I/II study in patients with advanced non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys 2002, 54(2 Suppl I):A2150.
24. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D'Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N: Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 2002, 20:804-810.
25. Shewach DS, Lawrence TS: Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 1995, 22(Suppl II):68-71.
26. Blackstock AW, Kwock L, Hess SM, Leadon SA, Tepper JE: Gemcitabine: In vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine an optimal dosing schedule - preclinical observations relevant to gemcitabine clinical trials [abstract]. Int J Radiat Oncol Biol Phys 1997, 39(2 Suppl 1):A141.
27. Lawrence TS, Eisbruch A, Shewach DS: Gemcitabine mediated radiosensitization. Semin Oncol 1997, 24(2 Suppl 7):S24-S28.
28. Groen H, Gregor A, Van Putten J, Van Der Leest A, Little F, Jungnelius U, Wets M, Price A: Phase I of gemcitabine (G) and high dose thoracic radiation (RT) in stage III non-small lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000, 19;A2123.
29. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE: Phase I trial of twice weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999, 17:2208-2212.
30. Zinner R, Fossella F, Komaki R, Jung M, Jhingran A, Glisson B, Pisters K, Stevens C, Khuri F, Kurie J, Lee J, Herbst R, Liao Z, Honget W: Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin; a phase I trial for patients with stage III non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2000, 19:A1996.
31. Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, John M, Herskovic A, Urtasun R, Asbell SO, Perez CA, Cox J: The impact of regional nodal radiotherapy (dose/volurne) on regional progression and survival in unresectable non-small call lung cancer: an analysis of RTOG data. Lung Cancer 2003, 41:207-214.
32. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002, 20:4191-4198.
33. Roychowdhury DF, Cassidy CA, Paterson P, Arning M: A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002, 20:311-315.
34. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA. Cole BF: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998, 4:1931-1936.
35. Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ: Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000, 36:2329-2334.